CR20210618A - Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopelículas - Google Patents

Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopelículas

Info

Publication number
CR20210618A
CR20210618A CR20210618A CR20210618A CR20210618A CR 20210618 A CR20210618 A CR 20210618A CR 20210618 A CR20210618 A CR 20210618A CR 20210618 A CR20210618 A CR 20210618A CR 20210618 A CR20210618 A CR 20210618A
Authority
CR
Costa Rica
Prior art keywords
methods
compositions
related lung
lung conditions
present
Prior art date
Application number
CR20210618A
Other languages
English (en)
Inventor
Ken Alibek
Sean Farmer
Original Assignee
Locus Ip Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Locus Ip Co Llc filed Critical Locus Ip Co Llc
Publication of CR20210618A publication Critical patent/CR20210618A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona materiales y métodos para prevenir, inhibir o reducir la formación de biopelículas (biofilm) y las infecciones por biopelículas, en particular, en el tracto respiratorio de un sujeto. La invención utiliza subproductos del crecimiento de microorganismos beneficiosos para mejorar la eficacia de las sustancias biocidas en el tratamiento, la alteración y / o la prevención de biopelículas. Ventajosamente, la presente invención es útil contra cepas bacterianas resistentes a antibióticos, tales como MRSA (Staphylococcus aureus resistente a la meticilina), Helicobacter pylori, S. pneumoniae, P. aeruginosa y A. fumigatus.
CR20210618A 2019-05-10 2020-05-08 Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopelículas CR20210618A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962846084P 2019-05-10 2019-05-10
PCT/US2020/032039 WO2020231786A1 (en) 2019-05-10 2020-05-08 Compositions and methods for treating biofilm-related lung conditions

Publications (1)

Publication Number Publication Date
CR20210618A true CR20210618A (es) 2022-03-11

Family

ID=73046991

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210618A CR20210618A (es) 2019-05-10 2020-05-08 Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopelículas

Country Status (13)

Country Link
US (2) US11890341B2 (es)
EP (1) EP3958869A4 (es)
JP (1) JP2022531929A (es)
KR (1) KR20210154872A (es)
CN (1) CN114080236A (es)
AU (1) AU2020276206A1 (es)
BR (1) BR112021022632A2 (es)
CA (1) CA3138922A1 (es)
CR (1) CR20210618A (es)
IL (1) IL287961A (es)
MX (1) MX2021013663A (es)
SG (1) SG11202112387UA (es)
WO (1) WO2020231786A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112008001301T5 (de) 2007-05-14 2010-04-29 Reserach Foundation Of State University Of New York Induktion einer physiologischen Dispersions-Antwort in Bakterien-Zellen in einem Biofilm
US20210069276A1 (en) * 2019-09-09 2021-03-11 LiquidPro Ltd. Ear spray device and ear protection composition for preventing water related ear canal disorders
US20210319900A1 (en) * 2020-04-14 2021-10-14 Siemens Healthcare Gmbh Cardiovascular assessment of patients suspected of having covid-19
US20230070870A1 (en) * 2021-09-09 2023-03-09 Robert V. West, III Covid Nasal Spray
BR102022016098A2 (pt) * 2022-08-12 2024-02-20 Universidade Estadual De Campinas Formulação antiviral e intranasal
CN115400105B (zh) * 2022-10-12 2023-08-22 湖北省农业科学院畜牧兽医研究所 焦棓酸在制备抗马链球菌兽疫亚种药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63182029A (ja) 1987-01-22 1988-07-27 Agency Of Ind Science & Technol リポソ−ム
EP0540074A1 (en) 1991-10-09 1993-05-05 ENIRICERCHE S.p.A. Cloning and sequencing of that chromosomal DNA region of bacillus subtilis comprising the SRFA operon which encodes the multienzymatic complex surfactin synthetase
JP2003246717A (ja) 2002-02-22 2003-09-02 Lion Corp 口腔用組成物
WO2005004895A2 (en) 2003-06-09 2005-01-20 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of growth hormone
WO2009090656A2 (en) 2008-01-18 2009-07-23 Hadasit Medical Research Services & Development Ltd. Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
WO2010036876A2 (en) 2008-09-25 2010-04-01 New York University Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
CN102414310B (zh) 2009-04-30 2015-05-06 阿克图杰尼斯公司 用于冷冻干燥乳酸菌的冷冻保护剂
AU2011247584B2 (en) * 2010-04-27 2016-01-14 Lysando Ag Method of reducing biofilms
US20150037307A1 (en) 2012-01-27 2015-02-05 Gfs Corporation Aus Pty Ltd. Poultry farm practices
JP2014034552A (ja) * 2012-08-09 2014-02-24 Kao Corp バイオフィルム形成抑制剤
CN103007287A (zh) 2012-09-29 2013-04-03 湖州紫金生物科技有限公司 一种鼠李糖脂作为药物口服促吸收剂的应用
US9585903B2 (en) * 2013-09-30 2017-03-07 Council Of Scientific & Industrial Research Pharmaceutical composition comprising sophorolipid in combination with an antibiotic
WO2015153961A1 (en) * 2014-04-03 2015-10-08 Yan-Yeung Luk Synthetic disugar hydrocarbons as natural analogos to control microbial behaviors
US9532986B2 (en) * 2014-04-08 2017-01-03 Aradigm Corporation Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
WO2015156904A1 (en) * 2014-04-08 2015-10-15 Aradigm Corporation Liposomes that form drug nanocrystals after freeze-thaw
EP3210619A2 (en) * 2014-10-24 2017-08-30 HPRD-Health Products Research and Development LDA Topical formulation for treating skin or mucosal infections, preparation method and uses thereof
CN109689854A (zh) * 2016-09-08 2019-04-26 轨迹Ip有限责任公司 用于高效生产和利用微生物源组合物的分布式系统

Also Published As

Publication number Publication date
AU2020276206A1 (en) 2021-12-02
CN114080236A (zh) 2022-02-22
MX2021013663A (es) 2022-01-24
IL287961A (en) 2022-01-01
WO2020231786A1 (en) 2020-11-19
BR112021022632A2 (pt) 2022-01-04
US20240181065A1 (en) 2024-06-06
EP3958869A4 (en) 2022-11-16
KR20210154872A (ko) 2021-12-21
EP3958869A1 (en) 2022-03-02
JP2022531929A (ja) 2022-07-12
US20200353085A1 (en) 2020-11-12
CA3138922A1 (en) 2020-11-19
SG11202112387UA (en) 2021-12-30
US11890341B2 (en) 2024-02-06

Similar Documents

Publication Publication Date Title
CR20210618A (es) Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopelículas
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
WO2016108045A3 (en) Antimicrobial compounds, compositions and methods
PH12019500360A1 (en) Antibiotic compounds
MX2019012877A (es) Prevencion, interrupcion y tratamiento de biopeliculas con lisina de bacteriofago.
WO2009126502A3 (en) Methods of inhibiting and treating biofilms using glycopeptide antibiotics
SG10201811361XA (en) Treatment of polybacterials infections
WO2018208987A3 (en) Antibacterial compounds
MX2011008043A (es) Derivados de actagardina.
WO2015100331A3 (en) Phenazine derivatives as antimicrobial agents
ZA202002093B (en) Antibacterial compounds
MX2021011147A (es) Materiales y metodos para mejorar el tratamiento y prevencion de las biopeliculas.
WO2013041663A3 (de) Modifizierte apidaecinderivate als antibiotische peptide
AU2012335397A8 (en) Novel bacteriophages
WO2010123599A3 (en) Anti-bacterial compositions and methods including targeting virulence factors of staphylococcus aureus
WO2015112093A3 (en) Antimicrobial peptidomimetics
WO2015035234A3 (en) Anti-microbial compounds and compositions
Anyanwu Assessment of the in vitro antibacterial activity of honey on some common human pathogens
WO2009124086A3 (en) Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections
EA201892278A1 (ru) Анбитактериальные биароматические производные с оксетан-3-илокси замещением
Gomes et al. Antimicrobial activity of phenolic extracts of Eucalyptus globulus and Juglans regia against dairy industry pathogens
WO2010131865A3 (ko) 항생제 내성 균주에 대한 항균용 조성물
EA201700519A2 (ru) АНТИМИКРОБНАЯ КОМБИНАЦИЯ В ОТНОШЕНИИ УСТОЙЧИВЫХ К КАРБАПЕНЕМАМ ГРАМОТРИЦАТЕЛЬНЫХ БАКТЕРИЙ ВИДА KLEBSIELLA PNEUMONIAE, ПРОДУЦИРУЮЩИХ МЕТАЛЛО-β-ЛАКТАМАЗУ
MX2014013637A (es) Metodos para prevencion de la formacion de biopelicula.
MX2023012943A (es) Compuesto antibacteriano.